ProShare Advisors LLC Increases Holdings in Intellia Therapeutics, Inc. by 17.7% in Q4 Fiscal Year

Institutional investor ProShare Advisors LLC has announced that it has increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.7% in the fourth quarter of the most recent fiscal year. According to the company’s latest filing with the Securities and Exchange Commission, ProShare Advisors now owns 18,735 shares of Intellia Therapeutics after buying an additional 2,819 shares during this period, totalling $654,000.

Intellia Therapeutics’ most recent earnings results were released on February 23rd, in which the company reported earnings per share of ($1.40) for the quarter – line with consensus estimates. Revenue for this period stood at $13.60m compared to analyst predictions of $10.71m, with a quarterly revenue increase of 5.4% YoY; however, Intellia Therapeutics did experience a negative return on equity of 48.70% and a negative net margin of 909.78%. In February last year compared to now, there has been an increase in sales growth for the business as well as an impressive earnings stability due to increased investment by companies like ProShare Advisors LLC.

For investors looking to keep abreast of how hedge funds are dealing with NTLA stock personally or insider-wise outside of what ProShares is doing should visit HoldingsChannel.com to see other hedge fund reports and insider trades related to Intellia Therapeutics Inc (NASDAQ:NTLA). For those who are committed to investing in NTLA long-term and seeing profit, bearing these data points announced along with current market reports or trends can help make informed decisions in their own time when allocating capital regardless if they’re looking to invest singularly or work together with their financial advisor colleagues within their family office investment firm for greater insight.

Looking forward into Q3/Q4 If Intellia continues building momentum, it is likely that more investors will take a position in the company, potentially leading to an upward trend for NTLA stock. Only time will tell how hedge funds maneuver around the stock but given recent changes and positive earnings reports, Intellia Therapeutics Inc looks to be sitting in a good position going forward.

Institutional Investors and Hedge Funds Show Interest in Intellia Therapeutics’ CRISPR/Cas9 Gene-Editing Technology for Curative Therapeutics


Intellia Therapeutics is a clinical-stage genome editing company that specializes in the development of curative therapeutics using CRISPR/Cas9 technology. The company’s focus on gene editing for therapeutic purposes has attracted a lot of attention from hedge funds and institutional investors.

DekaBank Deutsche Girozentrale grew its holdings in shares of Intellia Therapeutics by 21.2% in the third quarter, acquiring an additional 7,000 shares during the period. Avidian Wealth Solutions LLC also acquired a new stake in shares of Intellia Therapeutics in the same quarter, worth approximately $369,000.

The interest among institutional investors and hedge funds continued to grow as McGuire Investment Group LLC acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth approximately $1,224,000. Twinbeech Capital LP subsequently followed suit by acquiring a new stake in shares of Intellia Therapeutics worth approximately $5,398,000 by the end of 2023.

Finally, Continental Investors Services Inc. purchased 1,671,000 new stakes in the third quarter valued at approximately $169 million. Institutional investors and hedge funds own 85.61% of the company’s stock.

Intellia Therapeutics’ stock opened at $36.29 on Friday with a market capitalization of $3.20 billion and a price-to-earnings ratio of -5.87 beta of 1.86. The stock’s current valuation has led many equities research analysts to weigh in on NTLA shares recently.

Canaccord Genuity started coverage on Intellia Therapeutics with a “buy” rating and set a target price of $66 for the stock; whereas SVB Leerink instituted an “outperform” rating on it while lowering their target price from $86 to just $84 per share.

BMO Capital Markets upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $54.00 to $57.00 in a report on March 13th. Meanwhile, Chardan Capital lowered its target price on Intellia Therapeutics from $129 to $111 but still set the stock with a “buy” rating.

Finally, Citigroup upgraded Intellia Therapeutics’ rating from “sell” to “neutral,” lowering its target price for the company’s stock from $48 to $39 per share. According to data from Bloomberg, Intellia Therapeutics currently has an average rating of “Moderate Buy” with an average price objective of $85.67 per share.

In conclusion, the growing institutional interest and hedge fund investments in Intellia Therapeutics have exposed its strong potential in creating engineered cells that can treat immunological and oncological disorders among other diseases. While the ratings by equity research analysts may vary, there is a general agreement that their gene-editing innovation holds significant promise in transforming medicine and treating genetic diseases permanently by correcting disease-associated genes using CRISPR/Cas9 technology.

Read more here: Source link